WuXi XDC Cayman Past Earnings Performance
Past criteria checks 2/6
WuXi XDC Cayman has been growing earnings at an average annual rate of 52.8%, while the Life Sciences industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 58.6% per year. WuXi XDC Cayman's return on equity is 5.2%, and it has net margins of 13.4%.
Key information
52.8%
Earnings growth rate
43.6%
EPS growth rate
| Life Sciences Industry Growth | 41.4% |
| Revenue growth rate | 58.6% |
| Return on equity | 5.2% |
| Net Margin | 13.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How WuXi XDC Cayman makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,124 | 284 | 117 | 77 |
| 30 Sep 23 | 1,889 | 259 | 113 | 65 |
| 30 Jun 23 | 1,654 | 235 | 109 | 53 |
| 31 Mar 23 | 1,322 | 195 | 105 | 43 |
| 31 Dec 22 | 990 | 156 | 101 | 34 |
| 31 Dec 21 | 311 | 55 | 40 | 14 |
| 31 Dec 20 | 96 | 26 | 10 | 4 |
Quality Earnings: 2268 has high quality earnings.
Growing Profit Margin: 2268's current net profit margins (13.4%) are lower than last year (15.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2268's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 2268's past year earnings growth to its 5-year average.
Earnings vs Industry: 2268 earnings growth over the past year (82.1%) exceeded the Life Sciences industry -2.2%.
Return on Equity
High ROE: 2268's Return on Equity (5.2%) is considered low.